Compare NAC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAC | MESO |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | France | Australia |
| Employees | N/A | 81 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 1998 | N/A |
| Metric | NAC | MESO |
|---|---|---|
| Price | $11.80 | $16.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 712.0K | 276.9K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $629.74 |
| Revenue Next Year | N/A | $30.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.52 | $9.88 |
| 52 Week High | $12.25 | $21.50 |
| Indicator | NAC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 53.79 | 61.29 |
| Support Level | $11.78 | $14.44 |
| Resistance Level | $12.05 | $17.89 |
| Average True Range (ATR) | 0.11 | 0.53 |
| MACD | 0.03 | 0.29 |
| Stochastic Oscillator | 94.05 | 93.92 |
Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.